PMID- 23481700
OWN - NLM
STAT- MEDLINE
DCOM- 20140128
LR  - 20211021
IS  - 1535-9484 (Electronic)
IS  - 1535-9476 (Print)
IS  - 1535-9476 (Linking)
VI  - 12
IP  - 7
DP  - 2013 Jul
TI  - The human leukocyte antigen-presented ligandome of B lymphocytes.
PG  - 1829-43
LID - 10.1074/mcp.M112.024810 [doi]
AB  - Peptides presented by human leukocyte antigen (HLA) molecules on the cell surface 
      play a crucial role in adaptive immunology, mediating the communication between T 
      cells and antigen presenting cells. Knowledge of these peptides is of pivotal 
      importance in fundamental studies of T cell action and in cellular immunotherapy 
      and transplantation. In this paper we present the in-depth identification and 
      relative quantification of 14,500 peptide ligands constituting the HLA ligandome 
      of B cells. This large number of identified ligands provides general insight into 
      the presented peptide repertoire and antigen presentation. Our uniquely large set 
      of HLA ligands allowed us to characterize in detail the peptides constituting the 
      ligandome in terms of relative abundance, peptide length distribution, 
      physicochemical properties, binding affinity to the HLA molecule, and presence of 
      post-translational modifications. The presented B-lymphocyte ligandome is shown 
      to be a rich source of information by the presence of minor histocompatibility 
      antigens, virus-derived epitopes, and post-translationally modified HLA ligands, 
      and it can be a good starting point for solving a wealth of specific 
      immunological questions. These HLA ligands can form the basis for reversed 
      immunology approaches to identify T cell epitopes based not on in silico 
      predictions but on the bona fide eluted HLA ligandome.
FAU - Hassan, Chopie
AU  - Hassan C
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical 
      Center, Leiden, The Netherlands.
FAU - Kester, Michel G D
AU  - Kester MG
FAU - de Ru, Arnoud H
AU  - de Ru AH
FAU - Hombrink, Pleun
AU  - Hombrink P
FAU - Drijfhout, Jan Wouter
AU  - Drijfhout JW
FAU - Nijveen, Harm
AU  - Nijveen H
FAU - Leunissen, Jack A M
AU  - Leunissen JA
FAU - Heemskerk, Mirjam H M
AU  - Heemskerk MH
FAU - Falkenburg, J H Frederik
AU  - Falkenburg JH
FAU - van Veelen, Peter A
AU  - van Veelen PA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130312
PL  - United States
TA  - Mol Cell Proteomics
JT  - Molecular & cellular proteomics : MCP
JID - 101125647
RN  - 0 (HLA Antigens)
RN  - 0 (Ligands)
RN  - 0 (Peptides)
SB  - IM
MH  - Antigen Presentation
MH  - B-Lymphocytes/*metabolism
MH  - Cell Line, Transformed
MH  - HLA Antigens/*metabolism
MH  - Herpesvirus 4, Human/genetics
MH  - Humans
MH  - Ligands
MH  - Peptides/*metabolism
PMC - PMC3708169
EDAT- 2013/03/14 06:00
MHDA- 2014/01/29 06:00
PMCR- 2014/07/01
CRDT- 2013/03/14 06:00
PHST- 2013/03/14 06:00 [entrez]
PHST- 2013/03/14 06:00 [pubmed]
PHST- 2014/01/29 06:00 [medline]
PHST- 2014/07/01 00:00 [pmc-release]
AID - S1535-9476(20)32553-6 [pii]
AID - M112.024810 [pii]
AID - 10.1074/mcp.M112.024810 [doi]
PST - ppublish
SO  - Mol Cell Proteomics. 2013 Jul;12(7):1829-43. doi: 10.1074/mcp.M112.024810. Epub 
      2013 Mar 12.